- Home
- OCTO vs CERO Comparison
OCTO vs CERO Comparison
Compare OCTO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCTO
- CERO
- Stock Information
- Founded
- OCTO 1966
- CERO 2017
- Country
- OCTO United States
- CERO United States
- Employees
- OCTO N/A
- CERO N/A
- Industry
- OCTO
- CERO
- Sector
- OCTO
- CERO
- Exchange
- OCTO Nasdaq
- CERO Nasdaq
- Market Cap
- OCTO 4.2M
- CERO 3.5M
- IPO Year
- OCTO N/A
- CERO N/A
- Fundamental
- Price
- OCTO $1.23
- CERO $9.93
- Analyst Decision
- OCTO
- CERO Strong Buy
- Analyst Count
- OCTO 0
- CERO 2
- Target Price
- OCTO N/A
- CERO $45.00
- AVG Volume (30 Days)
- OCTO 14.2K
- CERO 3.3M
- Earning Date
- OCTO 08-13-2025
- CERO 08-13-2025
- Dividend Yield
- OCTO N/A
- CERO N/A
- EPS Growth
- OCTO N/A
- CERO N/A
- EPS
- OCTO N/A
- CERO N/A
- Revenue
- OCTO $41,576,562.00
- CERO N/A
- Revenue This Year
- OCTO N/A
- CERO N/A
- Revenue Next Year
- OCTO N/A
- CERO N/A
- P/E Ratio
- OCTO N/A
- CERO N/A
- Revenue Growth
- OCTO N/A
- CERO N/A
- 52 Week Low
- OCTO $0.98
- CERO $6.71
- 52 Week High
- OCTO $4.86
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- OCTO 47.54
- CERO 50.09
- Support Level
- OCTO $1.05
- CERO $8.12
- Resistance Level
- OCTO $1.24
- CERO $13.14
- Average True Range (ATR)
- OCTO 0.08
- CERO 2.83
- MACD
- OCTO -0.01
- CERO 0.39
- Stochastic Oscillator
- OCTO 50.00
- CERO 19.58
About OCTO Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.